Roche has acquired Signature Diagnostics AG, a privately held company based in Potsdam, Germany, focused on translational oncology and genomics. The company develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are constructed from multicenter prospective clinical studies. Signature uses the samples from its biobanks along with accompanying clinical progression and genetic data to develop and validate circulating cell free DNA (cfDNA) tests, which have the potential to advance non-invasive treatment response monitoring for patients with cancer.

Signature will be integrated into Roche Sequencing Unit and will continue to focus on expanding its innovative genomic signature portfolio.

Source: Signature Diagnostics